Roche solid in 2013 but modest dividend raises questions
This article was originally published in Scrip
True to expectation, Roche has reported a solid performance for the full year, and as the first of the European big pharma companies, it has likely set a trend for reporting negative currency effects among its peers (scripintelligence.com, 28 January 2014).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.